ethyl N-benzyl-7-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate | 179942-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl N-benzyl-7-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate
• 英文别名: ethyl 1-benzyl-7-bromo-4-oxo-1,4-dihydro-quinoline-3-carboxylate；Ethyl 1-benzyl-7-bromo-4-oxoquinoline-3-carboxylate
• CAS: 179942-68-8
• 化学式: C₁₉H₁₆BrNO₃
• 分子量: 386.245
• InChiKey: KCZCPJMKCGLXEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl N-benzyl-7-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 硫酸 、 氢溴酸 作用下， 生成 1-benzyl-7-bromo-N-bromobutyl-4-oxo-1,4-dihydroquinoline-3-carboxamide
  参考文献：
  名称：

  Rational Design of Partial Agonists for the Muscarinic M₁ Acetylcholine Receptor

  摘要：

  Aiming to design partial agonists for a G-protein-coupled receptor based on dynamic ligand binding, we synthesized three different series of bipharmacophoric ligands composed of the orthosteric building blocks iperoxo and 1 linked to allosteric modulators (BQCA-derived compounds, BQCAd; TBPB-derived compound, TBPBd). Their interactions were studied with the human muscarinic acetylcholine M-1-receptor (hM(1)) with respect to receptor binding and G(q)-protein signaling. Results demonstrate that iperoxo/BQCAd (2, 3) and 1/BQCAd hybrids (4) act as M1 partial agonists, whereas 1/TBPBd hybrids (5) did not activate M-1-receptors. Among the iperoxo/BQCAd-hybrids, spacer length in conjunction with the pattern of substitution tuned efficacy. Most interestingly, a model of dynamic ligand binding revealed that the spacer length of 2a and 3a controlled the probability of switch between the inactive purely allosteric and the active bitopic orthosteric/allosteric binding pose. In summary, dynamic ligand binding can be exploited in M-1 receptors to design partial agonists with graded efficacy.

  DOI：

  10.1021/jm500860w
• 作为产物：
  描述：

  diethyl 2-(((3-bromophenyl)amino)methylene)malonate 在 potassium carbonate 、 potassium iodide 作用下， 以 二苯醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 ethyl N-benzyl-7-bromo-4-oxo-1,4-dihydroquinoline-3-carboxylate
  参考文献：
  名称：

  Rational Design of Partial Agonists for the Muscarinic M₁ Acetylcholine Receptor

  摘要：

  Aiming to design partial agonists for a G-protein-coupled receptor based on dynamic ligand binding, we synthesized three different series of bipharmacophoric ligands composed of the orthosteric building blocks iperoxo and 1 linked to allosteric modulators (BQCA-derived compounds, BQCAd; TBPB-derived compound, TBPBd). Their interactions were studied with the human muscarinic acetylcholine M-1-receptor (hM(1)) with respect to receptor binding and G(q)-protein signaling. Results demonstrate that iperoxo/BQCAd (2, 3) and 1/BQCAd hybrids (4) act as M1 partial agonists, whereas 1/TBPBd hybrids (5) did not activate M-1-receptors. Among the iperoxo/BQCAd-hybrids, spacer length in conjunction with the pattern of substitution tuned efficacy. Most interestingly, a model of dynamic ligand binding revealed that the spacer length of 2a and 3a controlled the probability of switch between the inactive purely allosteric and the active bitopic orthosteric/allosteric binding pose. In summary, dynamic ligand binding can be exploited in M-1 receptors to design partial agonists with graded efficacy.

  DOI：

  10.1021/jm500860w

文献信息

• Substituted benzyl pyrimidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US05763450A1

  公开（公告）日：1998-06-09

  Compounds of the formula: ##STR1## in which R.sup.1 is lower alkoxy, R.sup.2 is bromine or lower alkoxy, and R.sup.3 is aryl, heteroaryl or a group --Q--R.sup.30, wherein Q is ethylene, vinylene or ethynylene and R.sup.30 is aryl, heteroaryl, lower alkoxycarbonyl or carbamoyl; hydrolyzable esters of carboxylic acids of formula I; and pharmaceutically acceptable salts of these compounds are useful for treating infectious diseases.

  公式为：##STR1## 其中 R.sup.1 是较低的烷氧基，R.sup.2 是溴或较低的烷氧基，R.sup.3 是芳基、杂环芳基或一个基团--Q--R.sup.30，其中 Q 是乙烯基、乙烯基或乙炔基，R.sup.30 是芳基、杂环芳基、较低的烷氧基羰基或氨基甲酰基；公式 I 的羧酸的可水解酯；以及这些化合物的药用可接受的盐，适用于治疗传染病。
• [EN] HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES D'URÉE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2009147433A1

  公开（公告）日：2009-12-10

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药用盐。还描述了它们的制备过程、含有它们的药物组成、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Choy Allison Laura

  公开号：US20100190745A1

  公开（公告）日：2010-07-29

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了式(I)的化合物及其药学上可接受的盐。还描述了它们的制备过程、含有它们的制药组合物、它们作为药物的使用以及它们在治疗细菌感染方面的使用。
• NOVEL BENZYL PYRIMIDINES
  申请人：Basilea Pharmaceutica AG

  公开号：EP0793656B1

  公开（公告）日：2003-03-26
• US5763450A
  申请人：——

  公开号：US5763450A

  公开（公告）日：1998-06-09